As a surrogate for post-treatment prognosis, REGS classifications were applied to the CLL samples with respect to R and C. Standard first-line treatment of CLL comprises a combined immune- and chemotherapeutic approach for patients without 17p- and/or inactivating TP53 mutations, often the FCR (fludarabine, cyclophosphamide, and rituximab) regimen [46–49]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.